This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
Provided informed consent to participate in the study;
Aged 18 years or older;
Fulfilled the 2019 EULAR/ACR classification criteria for SLE at the time of study entry;
Prescribed anifrolumab for SLE treatment for the first time, according to the approved Italian label and reimbursement criteria;
Patients who are at LLDAS5 at the time of study entry;
Previous exposure to anifrolumab;
Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy [mycophenolate mofetil (MMF)/cyclophosphamide (CYC) + high dose steroids], isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus
Currently participating in any interventional clinical trial with an investigational product;
AstraZeneca
Lead sponsor